Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 2: Pembrolizumab + Investigational Agents in Treatment-Naïve PD-L1+ Advanced NSCLC
NCT04165083Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of mk-4830, rolistobart in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jan 2021; status: completed.
02
Drugs
mk-4830rolistobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04165083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165083.